Coagulation Protein Disorders: all 31 studies
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)Enrolling by invitationNCT05768386
- An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4Results posted
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedNCT04323098Phase 3Results posted
- Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/2Results posted
- Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII InhibitorsCompletedNCT03734588Phase 1/2Results posted
- Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedNCT03520712Phase 1/2Results posted
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedNCT03417245Phase 3Results posted
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 3Results posted
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgCompletedNCT03392974Phase 3Results posted
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)CompletedNCT03370913Phase 3Results posted
- A Gene Transfer Study for Hemophilia ACompletedNCT03003533Phase 1/2Results posted
- Gene Therapy Study in Severe Haemophilia A Patients (270-201)CompletedNCT02576795Phase 1/2Results posted
- Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia ATerminatedNCT01434511Phase 3Results posted
- Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia ACompletedNCT01178294Phase 2/3Results posted
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 4
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 3
- A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanActive, not recruitingNCT06684314
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 1
- Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia AActive, not recruitingNCT06224907Phase 3
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 3
- Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation DeficienciesStatus unknownNCT04775888
- Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsCompletedNCT04684940Phase 1/2
- Stratifying Risk for Intracerebral HaemorrhageStatus unknownNCT04140812Not applicable
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BCompletedNCT03901755
- Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A ParticipantsCompletedNCT03876301
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceCompletedNCT03655340
- Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and BCompletedNCT03276130
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BCompletedNCT03055611
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT02976753
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 3
- Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)CompletedNCT01053169